
Prostate Cancer
Latest News
Latest Videos

CME Content
More News

An updated analysis, conducted after 11 years of observation, demonstrated continued improved outcomes with the addition of radiotherapy to oral antiandrogen therapy in men with locally advanced prostate cancer.

The androgen-receptor blocker enzalutamide (Xtandi) improves survival by nearly 30% in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) and delays progression of their disease by more than 80%

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses genomic assays in prostate cancer.

So many new agents for the treatment of men with castration-resistant prostate cancer (CRPC) have been introduced in the past several years that optimal sequencing of therapies remains an unsettled question.

Researchers in the Department of Radiation Oncology at the University of North Carolina Hospitals found that almost one-third of low-risk and almost one-half of intermediate-risk prostate cancer patients received a staging bone scan.

Bryan A. Mehlhaff, MD, from the Oregon Urology Institute, discusses prostate cancer screening guidelines.

Patients who undergo androgen deprivation therapy (ADT) to manage advanced prostate cancer will often face the prospect of a potentially dangerous testosterone surge before the downregulation of leuteinizing hormone (LH) secretion occurs and, within about 3 weeks, testosterone drops to castration-like levels.

Men who experience hot flashes because they are undergoing androgen-deprivation therapy for prostate cancer are not significantly helped by two treatments that alleviate that symptom in menopausal women, the results of a study show.










































































